Synthesis of [Phe(4F)3]thymopoietin II and examination of its immunological effect on the impaired blastogenic response of T-lymphocytes of uremic patients.
[Phe(4F)3]thymopoietin II was synthesized using a conventional solution method. The deprotection of the protected [Phe(4F)3]thymopoetin II was achieved by treatment with 1 M trifluoromethanesulfonic acid:thioanisole (molar ratio 1:1) in trifluoroacetic acid in the presence of dimethylselenide and m-cresol. The synthetic f1p4(4F)3]thymopoietin II and thymopoietin II were tested for effect on impaired T-lymphocyte transformation by phytohemagglutinin in uremic patients suffering from recurrent infectious diseases. The restoring activity on the impaired phytohemagglutinin stimulation of T-lymphocytes was obtained after incubation of peripheral lymphocytes isolated from uremic patients with the synthetic [Phe(4F)3]thymopoietin II. This peptide exhibited far stronger restoring effect than that of our synthetic thymopoietin II.
Abiko
T
T
Kidney Research Laboratory, Sendai, Japan.
Sekino
H
H
D000595:Amino Acid Sequence; D000818:Animals; D002417:Cattle; D002852:Chromatography, Ion Exchange; D005470:Fluorometry; D006801:Humans; D066298:In Vitro Techniques; D007239:Infections / Q000276:immunology; D008213:Lymphocyte Activation / Q000187:drug effects*; D008969:Molecular Sequence Data; D008970:Molecular Weight; D010835:Phytohemagglutinins / Q000494:pharmacology; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D013946:Thymopoietins / Q000138:chemical synthesis* / Q000494:pharmacology; D014511:Uremia / Q000276:immunology*
D010835:Phytohemagglutinins; D013946:Thymopoietins